Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Accumulated Expenses (2016 - 2018)

Historic Other Accumulated Expenses for Northwest Biotherapeutics (NWBO) over the last 5 years, with Q3 2018 value amounting to $6.2 million.

  • Northwest Biotherapeutics' Other Accumulated Expenses changed 0.0% to $6.2 million in Q3 2018 from the same period last year, while for Sep 2018 it was $6.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $6.2 million for FY2017, which is 0.0% changed from last year.
  • Per Northwest Biotherapeutics' latest filing, its Other Accumulated Expenses stood at $6.2 million for Q3 2018, which was down 0.0% from $6.2 million recorded in Q2 2018.
  • Northwest Biotherapeutics' 5-year Other Accumulated Expenses high stood at $6.2 million for Q4 2014, and its period low was $6.2 million during Q4 2014.
  • In the last 5 years, Northwest Biotherapeutics' Other Accumulated Expenses had a median value of $6.2 million in 2014 and averaged $6.2 million.
  • Data for Northwest Biotherapeutics' Other Accumulated Expenses shows a peak YoY increase of 0.0% (in 2015) and a maximum YoY decrease of 0.0% (in 2015) over the last 5 years.
  • Over the past 5 years, Northwest Biotherapeutics' Other Accumulated Expenses (Quarter) stood at $6.2 million in 2014, then changed by 0.0% to $6.2 million in 2015, then changed by 0.0% to $6.2 million in 2016, then changed by 0.0% to $6.2 million in 2017, then changed by 0.0% to $6.2 million in 2018.
  • Its last three reported values are $6.2 million in Q3 2018, $6.2 million for Q2 2018, and $6.2 million during Q1 2018.